Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery
Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson's disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater drug bioavailability, increased blood plasma concen...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
2022
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/160960 |